268 related articles for article (PubMed ID: 18563875)
1. How do azoles inhibit cytochrome P450 enzymes? A density functional study.
Balding PR; Porro CS; McLean KJ; Sutcliffe MJ; Maréchal JD; Munro AW; de Visser SP
J Phys Chem A; 2008 Dec; 112(50):12911-8. PubMed ID: 18563875
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode.
Seward HE; Roujeinikova A; McLean KJ; Munro AW; Leys D
J Biol Chem; 2006 Dec; 281(51):39437-43. PubMed ID: 17028183
[TBL] [Abstract][Full Text] [Related]
3. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.
McLean KJ; Carroll P; Lewis DG; Dunford AJ; Seward HE; Neeli R; Cheesman MR; Marsollier L; Douglas P; Smith WE; Rosenkrands I; Cole ST; Leys D; Parish T; Munro AW
J Biol Chem; 2008 Nov; 283(48):33406-16. PubMed ID: 18818197
[TBL] [Abstract][Full Text] [Related]
4. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.
Ji H; Zhang W; Zhou Y; Zhang M; Zhu J; Song Y; Lü J
J Med Chem; 2000 Jun; 43(13):2493-505. PubMed ID: 10891108
[TBL] [Abstract][Full Text] [Related]
5. Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450.
Lee JY; Kang NS; Kang YK
Biopolymers; 2012 Apr; 97(4):219-28. PubMed ID: 22113809
[TBL] [Abstract][Full Text] [Related]
6. Differential behavior of the sub-sites of cytochrome 450 active site in binding of substrates, and products (implications for coupling/uncoupling).
Narasimhulu S
Biochim Biophys Acta; 2007 Mar; 1770(3):360-75. PubMed ID: 17134838
[TBL] [Abstract][Full Text] [Related]
7. The Aspergillus fumigatus Damage Resistance Protein Family Coordinately Regulates Ergosterol Biosynthesis and Azole Susceptibility.
Song J; Zhai P; Zhang Y; Zhang C; Sang H; Han G; Keller NP; Lu L
mBio; 2016 Feb; 7(1):e01919-15. PubMed ID: 26908577
[TBL] [Abstract][Full Text] [Related]
8. Density functional theory applied to a difference in pathways taken by the enzymes cytochrome P450 and superoxide reductase: spin States of ferric hydroperoxo intermediates and hydrogen bonds from water.
Surawatanawong P; Tye JW; Hall MB
Inorg Chem; 2010 Jan; 49(1):188-98. PubMed ID: 19968237
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450-The Wonderful Nanomachine Revealed through Dynamic Simulations of the Catalytic Cycle.
Dubey KD; Shaik S
Acc Chem Res; 2019 Feb; 52(2):389-399. PubMed ID: 30633519
[TBL] [Abstract][Full Text] [Related]
10. An enlarged, adaptable active site in CYP164 family P450 enzymes, the sole P450 in Mycobacterium leprae.
Agnew CR; Warrilow AG; Burton NM; Lamb DC; Kelly SL; Brady RL
Antimicrob Agents Chemother; 2012 Jan; 56(1):391-402. PubMed ID: 22037849
[TBL] [Abstract][Full Text] [Related]
11. Imidazolyl carboxylic acids as mechanistic probes of flavocytochrome P-450 BM3.
Noble MA; Quaroni L; Chumanov GD; Turner KL; Chapman SK; Hanzlik RP; Munro AW
Biochemistry; 1998 Nov; 37(45):15799-807. PubMed ID: 9843385
[TBL] [Abstract][Full Text] [Related]
12. Electronic properties of pentacoordinated heme complexes in cytochrome P450 enzymes: search for an Fe(I) oxidation state.
Porro CS; Kumar D; de Visser SP
Phys Chem Chem Phys; 2009 Nov; 11(43):10219-26. PubMed ID: 19865780
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives.
Lewis DF; Wiseman A; Tarbit MH
J Enzyme Inhib; 1999; 14(3):175-92. PubMed ID: 10445042
[TBL] [Abstract][Full Text] [Related]
14. NMR studies of substrate binding to cytochrome P450 BM3: comparisons to cytochrome P450 cam.
Modi S; Primrose WU; Boyle JM; Gibson CF; Lian LY; Roberts GC
Biochemistry; 1995 Jul; 34(28):8982-8. PubMed ID: 7619797
[TBL] [Abstract][Full Text] [Related]
15. Docking analysis of a series of cytochrome P-450(14) alpha DM inhibiting azole antifungals.
Talele TT; Hariprasad V; Kulkarni VM
Drug Des Discov; 1998 May; 15(3):181-90. PubMed ID: 9689500
[TBL] [Abstract][Full Text] [Related]
16. Effects of Y132H and F145L substitutions on the activity, azole resistance and spectral properties of Candida albicans sterol 14-demethylase P450 (CYP51): a live example showing the selection of altered P450 through interaction with environmental compounds.
Kudo M; Ohi M; Aoyama Y; Nitahara Y; Chung SK; Yoshida Y
J Biochem; 2005 May; 137(5):625-32. PubMed ID: 15944416
[TBL] [Abstract][Full Text] [Related]
17. Structural diversities of active site in clinical azole-bound forms between sterol 14alpha-demethylases (CYP51s) from human and Mycobacterium tuberculosis.
Matsuura K; Yoshioka S; Tosha T; Hori H; Ishimori K; Kitagawa T; Morishima I; Kagawa N; Waterman MR
J Biol Chem; 2005 Mar; 280(10):9088-96. PubMed ID: 15611056
[TBL] [Abstract][Full Text] [Related]
18. A comparison of steroid and lipid binding cytochrome P450s from Mycobacterium marinum and Mycobacterium tuberculosis.
Child SA; Ghith A; Bruning JB; Bell SG
J Inorg Biochem; 2020 Aug; 209():111116. PubMed ID: 32473484
[TBL] [Abstract][Full Text] [Related]
19. Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.
Mast N; Zheng W; Stout CD; Pikuleva IA
Mol Pharmacol; 2013 Jul; 84(1):86-94. PubMed ID: 23604141
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of human CYP51 inhibition by antifungal azoles.
Strushkevich N; Usanov SA; Park HW
J Mol Biol; 2010 Apr; 397(4):1067-78. PubMed ID: 20149798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
